樂
樂觀
樂觀 · 25%PPBT
$2.79
情境價格
$1.280
+0.031 (+2.40%)收盤時
Loading chart…
- 最高
- 1.330
- 開盤
- 1.150
- 成交量加權均價
- 1.25
- 成交量
- 42.46K
- 市值
- 11.43M
- 最低
- 1.150
- 成交金額
- 53.22K
- 企業價值/稅息折舊攤銷前利潤（TTM）
- 0.00
Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.
AI 分析 of Purple Biotech Ltd (PPBT)
持有Currently, Purple Biotech Ltd is not a strong buy due to its significant financial losses and high volatility. The current price is $1.28, with a 52-week high of $8.90, indicating a potential for recovery but also a risk of further decline. The RSI is at 70.565, suggesting it may be overbought, and the forward P/E ratio is 0, indicating uncertainty in future earnings. The main risk is the projected EPS loss of -2.88 for the upcoming earnings report, which could further impact investor sentiment.
估值指標
Purple Biotech Ltd（PPBT）目前預期本益比為 0.00，5 年平均預期本益比為 -7.75。
Alphio AI 對 PPBT 的價格情境
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重（25 / 50 / 25），不構成保證。
事件時間軸
資訊
8.509-02NewsfilterPurple Biotech Secures Patent Allowance for Tri-Specific Antibodies
- 8.506-11Newsfilter
Purple Biotech's IM1240 Study Advances with Promising Results
9.505-15seekingalphaPurple Biotech Reports Q1 2026 Financial Results
9.004-23moomooPURPLE BIOTECH LTD FORMS SCIENTIFIC ADVISORY BOARD FOR CAPTN-3 ANTIBODY PLATFORM
7.503-25moomooPurple Biotech Partners with Converge Bio to Enhance Development of Next-Generation Tri-Specific Antibody Platform Using AI
PPBT 常見問題 —— 由 Alphio AI 解答
Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Currently, Purple Biotech Ltd is not a strong buy due to its significant financial losses and high volatility. The current price is $1.28, with a 52-week high of $8.90, indicating a potential for recovery but also a risk of further decline. The RSI is at 70.565, suggesting it may be overbought, and the forward P/E ratio is 0, indicating uncertainty in future earnings. The main risk is the projected EPS loss of -2.88 for the upcoming earnings report, which could further impact investor sentiment.
社群
更多 ↗暫無貼文
註冊或登入後參與討論相關文章
- CPI Report and the Stock Market: How to Read October 2026 Inflation Data Before the Fed DecidesOctober 2026 CPI lands Nov 10 with no year-over-year number and Fed hike odds near 80%. Learn how to read CPI, which stocks react, and how to plan for it.
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。